Shri Ahimsa Naturals Ltd
SHRIAHIMSAShri Ahimsa Naturals Ltd's price has outrun its earnings. +97.9% in a year against EPS +32.3% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +97.9% in a year while annual EPS moved +32.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (72 weeks in) while the P/E sits at the 99th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +25.0% year on year, and 84% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Shri Ahimsa Naturals Ltd trades at ₹462, in a confirmed uptrend and 72 weeks into that stage. That is +41.0% against its own 200-day average. It sits at 88% of a 52-week range of ₹222 to ₹494. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 6 straight weeks.
Today the stock is in a confirmed uptrend — week 72 of stage 2, confirmed. At ₹462 it trades +41.0% versus its 200-day average and sits at 88% of its 52-week range (₹222–₹494).
Against the market, two honest reads. Cumulative: over the last 1.4 years the stock moved +213% while the NIFTY 500 moved +12% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Shri Ahimsa Naturals Ltd trades at 37.2× P/E, about the priciest it has ever traded. Its long-run median P/E is 21.0×, measured across 1.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 37.2× is about the priciest it has ever traded, against a long-run median of 21.0× measured over 1.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +32.3% against a +97.9% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Shri Ahimsa Naturals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +28.1% | +5.8% | — | — |
| Profit | +31.8% | −8.6% | — | — |
| EPS | +32.3% | −44.6% | — | — |
| Share price | +97.9% | — | — | — |
4-Factor Sector Score
61.0/100 — rank 5 of 20 in Chemicals - Organic · 56% evidence confidence
Shri Ahimsa Naturals Ltd scores 61.0 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 5. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 18.9 + 18 + 10 + 14.1 = 61. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Shri Ahimsa Naturals Ltd reported ₹63.0 Cr of revenue in the Mar 26 quarter, +14.5% year on year. That is the 2nd straight quarter of year-on-year growth. Over 3 years it has compounded at 5.8% a year. The last full year, FY26, came in at ₹123 Cr. The last four reported quarters add to ₹220 Cr.
FY26 revenue came in at ₹123 Cr (+28.1% on the year), capping 3 years at 5.8% compound. The latest quarter (Mar 26) printed ₹63.0 Cr, +14.5% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +31.6% growth against the decade's 5.8% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Shri Ahimsa Naturals Ltd's operating margin is 28.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 29.0% to 48.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 28.0%, −2.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 29.0%–48.0%.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Shri Ahimsa Naturals Ltd earned ₹15.0 Cr of net profit in the Mar 26 quarter, +25.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹29.0 Cr. The 3-year compound rate is −8.6%. That is 23.8% of the quarter's revenue.
Mar 26 profit was ₹15.0 Cr, +25.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹29.0 Cr (+31.8%), and the 3-year compound rate is −8.6%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 84% of Shri Ahimsa Naturals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹9.0 Cr of operating cash against ₹29.0 Cr of profit. After ₹15.0 Cr of capital spending, ₹−6.0 Cr was left as free cash.
FY26: operating cash of ₹9.0 Cr against reported profit of ₹29.0 Cr, leaving free cash of ₹−6.0 Cr after ₹15.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 84% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 84%: the cash cycle stretched 123 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 7.4× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Shri Ahimsa Naturals Ltd's cash conversion cycle runs 277 days in FY26, up from 154 days in FY23. Capital spending ran ₹37.0 Cr over the last 3 years. At FY26 sales of ₹123 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹93.0 Cr sits inside the business at any moment.
FY26: debtors at 86 days, inventory at 193 days — roughly 6.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 277 days, looser than FY23's 154.
The full loop: cash goes out to suppliers and production on day 0; stock waits 193 days to sell; customers pay about 86 days after that; and suppliers themselves are paid at 2 days — netting out to the 277-day cycle.
In money terms: at FY26 sales of ₹123 Cr, each day of the cycle holds about ₹0.3 Cr — so the 277-day loop keeps roughly ₹93.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹37.0 Cr over the last 3 fiscal years against ₹5.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹18.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Shri Ahimsa Naturals Ltd earns a ROCE of 22% in FY26. Return on invested capital clears the cost of that capital by +7.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 23.6% net margin on 0.56× asset turns.
FY26 ROCE is 22%.
Why the return is what it is — the wiring (FY26): 23.6% net margin × 0.56× asset turns × 1.13× balance-sheet leverage ≈ 14.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 19.8% − 12.0% = a +7.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Shri Ahimsa Naturals Ltd carries ₹20.0 Cr of borrowings against ₹193 Cr of equity in FY26, a debt-to-equity of 0.10. Operating profit covers the interest bill 36×. Over 3 years borrowings went from ₹3.0 Cr to ₹20.0 Cr. Capital spending ran ₹37.0 Cr across the last 3 of those years.
FY26: borrowings of ₹20.0 Cr against equity of ₹193 Cr — a debt-to-equity of 0.10. Operating profit covers the interest bill 36×. Over 3 years borrowings went from ₹3.0 Cr to ₹20.0 Cr while capital spending ran ₹37.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Shri Ahimsa Naturals Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Shri Ahimsa Naturals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Valiant Organics LtdVALIANTORG | 63.2/100Mixed-positive evidence87% evidence | TURNING | 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence | 10.8/25 ROCE 5.5% · OPM 18% 95% evidence | 11.0/20 P/E 22× · PEG — 50% evidence | 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Foseco India LtdFOSECOIND | 63.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence | 16.9/25 ROCE 17.4% · OPM 23% 100% evidence | 11.5/20 P/E 44.8× · PEG 1.31 65% evidence | 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elantas Beck India LtdELANTAS | 62.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence | 19.1/25 ROCE 21.2% · OPM 29% 76% evidence | 6.3/20 P/E 64.8× · PEG — 50% evidence | 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence |
| Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4OCCL LtdOCCLLTD | 61.4/100Mixed-positive evidence60% evidence | BREAKING OUT | 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.2/25 ROCE 13% · OPM 28% 76% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shri Ahimsa Naturals Ltdthis pageSHRIAHIMSA | 61.0/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 18.0/25 ROCE 21.7% · OPM 28% 95% evidence | 10.0/20 P/E 37.2× · PEG — 15% evidence | 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Indo Amines LtdINDOAMIN | 60.6/100Mixed-positive evidence81% evidence | BASING | 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence | 16.8/25 ROCE 19.9% · OPM 14% 95% evidence | 14.0/20 P/E 11.3× · PEG — 50% evidence | 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Balaji Amines LtdBALAMINES | 59.3/100Mixed-positive evidence82% evidence | LEADER | 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.3/25 ROCE 11% · OPM 25% 76% evidence | 7.0/20 P/E 36.1× · PEG — 50% evidence | 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nitta Gelatin India LtdNITTAGELA | 59.2/100Mixed-positive evidence72% evidence | TURNING | 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence | 19.1/25 ROCE 27.7% · OPM 24% 95% evidence | 9.7/20 P/E 14.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence |
| Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9BASF India LtdBASF | 52.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence | 10.7/25 ROCE 14.5% · OPM 10% 100% evidence | 14.3/20 P/E 25.7× · PEG 1.62 100% evidence | 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GFL LtdGFLLIMITED | 51.5/100Mixed-positive evidence72% evidence | BREAKING OUT | 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence | 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Laxmi Organic Industries LtdLXCHEM | 49.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.4/25 ROCE 4.7% · OPM 12% 100% evidence | 14.7/20 P/E 38.8× · PEG 1.14 100% evidence | 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 45.6/100Mixed-negative evidence100% evidence | BREAKING OUT | 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence | 17.6/25 ROCE 21.5% · OPM 25% 100% evidence | 7.2/20 P/E 36.2× · PEG 2.7 100% evidence | 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jyoti Resins and Adhesives LtdJYOTIRES | 43.1/100Mixed-negative evidence69% evidence | 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence | 19.2/25 ROCE 36.5% · OPM 14% 76% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sigachi Industries LtdSIGACHI | 41.5/100Mixed-negative evidence79% evidence | BREAKING OUT | 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence | 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence | 8.4/20 P/E 64.5× · PEG — 50% evidence | 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Shree Ganesh Remedies LtdSGRL | 41.1/100Mixed-negative evidence76% evidence | 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence | 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence | 7.1/20 P/E 54.8× · PEG — 50% evidence | 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Oriental Aromatics LtdOAL | 36.0/100Mixed-negative evidence74% evidence | BREAKING OUT | 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 337× · PEG — 15% evidence | 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Fairchem Organics LtdFAIRCHEMOR | 33.6/100Adverse evidence87% evidence | BREAKING OUT | 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 6.0/25 ROCE 3.3% · OPM 10% 95% evidence | 8.0/20 P/E 52× · PEG — 50% evidence | 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Gem Aromatics LtdGEMAROMA | 24.4/100Adverse evidence65% evidence | ASLEEP | 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence | 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence | 8.5/20 P/E 772.2× · PEG — 15% evidence | 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Sacheerome LtdSACHEEROME | 59.1/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.3/25 ROCE 35.7% · OPM 23% 95% evidence | 9.7/20 P/E 40.1× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence |
| Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 36.7/100Thin evidence · provisional27% evidence | 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence | 4.9/25 ROCE -2150% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Shri Ahimsa Naturals Ltd's share price today?
Shri Ahimsa Naturals Ltd trades at ₹462, +97.9% over the past year. The company is valued at ₹1,083 Cr. The stock sits at 88% of its 52-week range of ₹222–₹494, +41.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 72 weeks in. — as of 11 September 2026.
What were Shri Ahimsa Naturals Ltd's latest quarterly results?
Shri Ahimsa Naturals Ltd reported revenue of ₹63.0 Cr and net profit of ₹15.0 Cr for the Mar 26 quarter. Revenue rose 14.5% and profit rose 25.0% year on year. Earnings per share were ₹6.23. The operating margin was 28.0%, 2.0 pp lower than a year earlier. — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's revenue?
Shri Ahimsa Naturals Ltd reported revenue of ₹63.0 Cr in the Mar 26 quarter, +14.5% year on year. For the full FY26 fiscal year, revenue was ₹123 Cr (+28.1%). Over the last 3 years revenue compounded at 5.8% a year. — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's profit?
Shri Ahimsa Naturals Ltd earned ₹15.0 Cr of net profit in the Mar 26 quarter, +25.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹29.0 Cr. The operating margin ran 28.0% in the latest quarter. — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's market cap?
Shri Ahimsa Naturals Ltd's market capitalisation is ₹1,083 Cr at a share price of ₹462. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's P/E ratio?
Shri Ahimsa Naturals Ltd trades at a P/E of 37.2×, at the 99th percentile of its own 1-year range, against a long-run median of 21.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Shri Ahimsa Naturals Ltd pay a dividend?
No — Shri Ahimsa Naturals Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd overvalued?
On its own history, Shri Ahimsa Naturals Ltd looks expensive: its P/E of 37.2× sits at the 99th percentile of its 1-year range (long-run median 21.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd growing?
Yes — Shri Ahimsa Naturals Ltd is growing: latest-quarter revenue +14.5% year on year, profit +25.0%, and the margin −2.0 pp at 28.0%. The 3-year compound rates are 5.8% (revenue) and −8.6% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Shri Ahimsa Naturals Ltd performing?
Shri Ahimsa Naturals Ltd is in a confirmed uptrend, 72 weeks in. Its latest quarter's revenue rose 14.5% and profit rose 25.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 72 of stage 2), trading +41.0% versus its 200-day average and at 88% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd beating the market?
On recent form, yes — Shri Ahimsa Naturals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 6 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.4 years the stock moved +213% against the NIFTY 500's +12% — ahead of the index over the full window. — as of 11 September 2026.
Will Shri Ahimsa Naturals Ltd's share price go up?
This page publishes no price forecast for Shri Ahimsa Naturals Ltd. What it measures instead: the share price is ₹462, the price is in a confirmed uptrend 72 weeks in. Its P/E of 37.2× sits at the 99th percentile of its own 1-year range. — as of 11 September 2026.
Who owns Shri Ahimsa Naturals Ltd?
Promoters hold 68.4% of Shri Ahimsa Naturals Ltd, foreign institutions 0.4%, domestic institutions 5.8% and the public 25.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Shri Ahimsa Naturals Ltd have too much debt?
No — Shri Ahimsa Naturals Ltd's debt-to-equity is 0.10, and operating profit covers the interest bill 36×. FY26 borrowings were ₹20.0 Cr against equity of ₹193 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's capex?
Shri Ahimsa Naturals Ltd spent ₹37.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹15.0 Cr, with ₹18.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Shri Ahimsa Naturals Ltd's cash flow?
Shri Ahimsa Naturals Ltd generated ₹9.0 Cr of operating cash flow in FY26 and ₹−6.0 Cr of free cash flow after ₹15.0 Cr of capital spending. Reported profit that year was ₹29.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 84% of Shri Ahimsa Naturals Ltd's reported profit arrived as operating cash. Though the latest year ran at 31% — the trend is the thing to watch. In FY26, operating cash was ₹9.0 Cr against reported profit of ₹29.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Shri Ahimsa Naturals Ltd in its business cycle?
Shri Ahimsa Naturals Ltd's FY26 operating margin was 29.0%, against a 4-year band of 29.0%–48.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 28.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Shri Ahimsa Naturals Ltd story?
The sharpest disagreement: the price moved +97.9% in a year while annual EPS moved +32.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Shri Ahimsa Naturals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Shri Ahimsa Naturals Ltd's price has outrun its earnings. +97.9% in a year against EPS +32.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!